AbbVie

Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
BioSpace
AbbVie
Skyrizi
ulcerative colitis
lupus
Rinvoq
clinical trials
Flag link:
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
Fierce Pharma
AbbVie
Skyrizi
IBD
ulcerative colitis
clinical trials
Flag link:
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
EP Vantage
AAD
hidradenitis suppurativa
AbbVie
Humira
UCB Pharma
Bimzelx
Acelyrin
izokibep
Flag link:
AbbVie’s Skyrizi hits the spot in refractory psoriasis
AbbVie’s Skyrizi hits the spot in refractory psoriasis
Pharmaphorum
AbbVie
Skyrizi
psoriasis
Flag link:
AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate
AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate
Fierce Pharma
Pfizer
AbbVie
Humira
drug pricing
inflation
Flag link:
AbbVie braces for 'greater erosion' of Humira franchise in second half of this year
AbbVie braces for 'greater erosion' of Humira franchise in second half of this year
Endpoints
AbbVie
Humira
Rinvoq
Flag link:
AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff
AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff
Fierce Pharma
AbbVie
Pharma CEOs
executive pay
Humira
Richard Gonzalez
Flag link:
AbbVie and Capsida Biotherapeutics partner on eye disease focused gene therapies
AbbVie and Capsida Biotherapeutics partner on eye disease focused gene therapies
Biopharma Reporter
AbbVie
Capsida Biotherapeutics
eye disease
drug development
Flag link:
AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases
AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases
BioSpace
AbbVie
Capsida Biotherapeutics
gene therapy
eye disease
Flag link:
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Flag link:
Years after the first US biosim launches, doctors still have their concerns: survey
Years after the first US biosim launches, doctors still have their concerns: survey
Fierce Pharma
biosimilars
PBMs
physicians
AbbVie
Humira
Amgen
Amjevita
Flag link:
The world needs Garp, according to Abbvie
The world needs Garp, according to Abbvie
EP Vantage
AbbVie
GARP
Argenx
R&D
Flag link:
AbbVie talks next steps as first Humira competitor makes it to market
AbbVie talks next steps as first Humira competitor makes it to market
Endpoints
AbbVie
Humira
biosimilars
Rick Gonzalez
Flag link:
AbbVie opens up to bigger deals as competition heats up
AbbVie opens up to bigger deals as competition heats up
Endpoints
AbbVie
Humira
Flag link:
After AbbVie, Teva walks away from influential trade group PhRMA
After AbbVie, Teva walks away from influential trade group PhRMA
Fierce Pharma
Teva Pharmaceutical
PhRMA
AbbVie
lobbying
Flag link:
Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita
Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita
Forbes
Amgen
Amjevita
AbbVie
Humira
biosimilars
drug pricing
Flag link:
Amgen launches Humira biosimilar, releases Q4 earnings report
Amgen launches Humira biosimilar, releases Q4 earnings report
Medical Marketing and Media
Amgen
Humira
biosimilars
earnings
AbbVie
Amjevita
Flag link:
Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug
Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug
BioPharma Dive
AbbVie
Humira
biosimilars
Amgen
Flag link:
The end of the Humira era
The end of the Humira era
EP Vantage
AbbVie
Humira
patents
biosimilars
Merck
Keytruda
Flag link:

Pages